Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Discovery and hit-to-lead optimization of benzothiazole scaffold-based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa
ID
Cotman, Andrej Emanuel
(
Author
),
ID
Durcik, Martina
(
Author
),
ID
Benedetto Tiz, Davide
(
Author
),
ID
Fulgheri, Federica
(
Author
),
ID
Secci, Daniela
(
Author
),
ID
Sterle, Maša
(
Author
),
ID
Možina, Štefan
(
Author
),
ID
Skok, Žiga
(
Author
),
ID
Zidar, Nace
(
Author
),
ID
Zega, Anamarija
(
Author
),
ID
Ilaš, Janez
(
Author
),
ID
Peterlin-Mašič, Lucija
(
Author
),
ID
Tomašič, Tihomir
(
Author
),
ID
Kikelj, Danijel
(
Author
), et al.
PDF - Presentation file,
Download
(7,98 MB)
MD5: 2EF0E995627D74F4171CA528F2DAD8EF
URL - Source URL, Visit
https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01597
Image galllery
Abstract
We have developed compounds with a promising activity against Acinetobacter baumannii and Pseudomonas aeruginosa, which are both on the WHO priority list of antibiotic-resistant bacteria. Starting from DNA gyrase inhibitor 1, we identified compound 27, featuring a 10-fold improved aqueous solubility, a 10-fold improved inhibition of topoisomerase IV from A. baumannii and P. aeruginosa, a 10-fold decreased inhibition of human topoisomerase IIα, and no cross-resistance to novobiocin. Cocrystal structures of 1 in complex with Escherichia coli GyrB24 and (S)-27 in complex with A. baumannii GyrB23 and P. aeruginosa GyrB24 revealed their binding to the ATP-binding pocket of the GyrB subunit. In further optimization steps, solubility, plasma free fraction, and other ADME properties of 27 were improved by fine-tuning of lipophilicity. In particular, analogs of 27 with retained anti-Gram-negative activity and improved plasma free fraction were identified. The series was found to be nongenotoxic, nonmutagenic, devoid of mitochondrial toxicity, and possessed no ion channel liabilities.
Language:
English
Keywords:
antibacterial activity
,
bacteria
,
genetics
,
inhibitors
,
solubility
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
Str. 1380–1425
Numbering:
Vol. 66, iss. 2
PID:
20.500.12556/RUL-144326
UDC:
615.015.8
ISSN on article:
1520-4804
DOI:
10.1021/acs.jmedchem.2c01597
COBISS.SI-ID:
138544899
Publication date in RUL:
14.02.2023
Views:
665
Downloads:
146
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of medicinal chemistry
Shortened title:
J. med. chem.
Publisher:
American Chemical Society
ISSN:
1520-4804
COBISS.SI-ID:
512806681
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
antibakterijsko delovanje
,
zaviralci
,
topnost
,
genetika
,
bakterije
,
bakterijska rezistenca
Projects
Funder:
EC - European Commission
Funding programme:
FP7
Project number:
115583
Name:
European Gram Negative Antibacterial Engine
Acronym:
ENABLE
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
ARRS - Slovenian Research Agency
Project number:
J1-3030
Name:
MTAvsAMR: novi večtarčni antibiotiki proti večkratno odpornim bakterijam
Funder:
ARRS - Slovenian Research Agency
Project number:
J1-3031
Name:
Razvoj novih zaviralcev bakterijskih topoizomeraz za boj proti odpornim infekcijam
Funder:
RCUK - Research Council UK
Funding programme:
BBSRC
Project number:
BB/J014524/1
Funder:
Other - Other funder or multiple funders
Funding programme:
Redx Pharma Plc, iCASE studentship
Funder:
WT - Wellcome Trust
Funding programme:
Investigator Award
Project number:
110072/Z/15/Z
Funder:
RCUK - Research Council UK
Funding programme:
BBSRC, Institute Strategic Programme
Project number:
BB/P012523/1
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back